An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. - Wikidata - awgldk - TriplyDB

An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.

An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.

http://www.wikidata.org/entity/Q39697622

about

Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs)Interkingdom Pharmacology of Angiotensin-I Converting Enzyme Inhibitor Phosphonates Produced by Actinomycetes Recommendations for the management of cough in adults.Using routinely collected prescribing data to determine drug persistence for the purpose of pharmacovigilance.Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema.Angiotensin-converting enzyme inhibitors and angioedema.Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berinert®): about one case and review of the therapeutic arsenal.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials.Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.Factors that favor the occurrence of cough in patients treated with ramipril--a pharmacoepidemiological study.Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.The prince and the pauper. A tale of anticancer targeted agents.Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.Clinical Immunology Review Series: An approach to the patient with angio-oedema.Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.Angiotensin-converting enzyme inhibitor-associated angioedema treated with c1-esterase inhibitor: A case report and review of the literature.ACE-I induced angioedema: a case report and review of literature.Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues.Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis.Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis.Risk factors associated with severe and recurrent angioedema: an epidemic linked to ACE-inhibitors.Case-control study evaluating competing risk factors for angioedema in a high-risk population.Antihypertensive drug associated angioedema: effect modification by race/ethnicity.Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors.Fatal laryngeal angioedema: a case report and a workup of angioedema in a forensic setting.Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.Refractory Angioedema in a Patient with Systemic Lupus Erythematosus.Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease.Life threatening angioedema in a patient on ACE inhibitor (ACEI) confined to the upper airway.Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature.Antioxidant and ACE Inhibitory Bioactive Peptides Purified from Egg Yolk Proteins.Pharmacogenomics of antihypertensive drug response: new evidence of miRNA controlling blood pressure.

P2860

Q26851935-97467A9E-C165-4710-9678-80EEEF34D244 Q27684235-54013496-AFD1-43AA-BA15-55B1BB96DE2B Q28260345-3DDD9E35-E19C-43C2-BFE9-D8DA62B3783C Q33558310-F10D855D-9648-4CA3-8409-35851D95BF2E Q33702327-FBB6C9AD-C903-43FC-B157-11E18B6AD9BA Q33940776-7D079B1F-A639-4725-A389-A0FEF71BB594 Q34153767-A7178609-76C5-47F8-818B-BD9EE70D4057 Q34232188-4CA81298-052E-433F-B513-2CD837E83582 Q34512406-55E6E6B0-5750-45D0-B9E5-3C37DCDC06E7 Q35155766-F7DB992B-8B07-421E-BA77-A25AA87954EE Q35539305-2AD4BF7D-7460-46C9-A3A8-DA9FB4A9AAB9 Q35684200-82592531-01D5-4461-89FE-A15BECE0ADB9 Q36053760-2641B6B4-E839-4648-AF27-CE8D4B607AC1 Q36203442-19F2F7E0-77FC-4469-B0AF-C491E9DBA95E Q36497887-B5942CC4-F8F6-406E-863E-432F6BC65657 Q36577076-5C75D927-9A07-4983-9741-3D63DECFA5D5 Q36638095-801BB38B-C156-4BF9-B33C-9F2A1B211506 Q37042365-220A64AE-20C9-401D-90F8-881E4EB2CF01 Q37359802-0B81FDB1-D483-4C1A-A688-766809EA5A0F Q37394385-A3EB90A6-EB75-497E-B090-7A0CBB8A008A Q37524447-35624114-DF1B-4E6A-A20E-62FF06785AE5 Q37593085-63C5E628-2C24-4ED9-86CA-7C084D366C14 Q37615028-5283D4A2-38B8-498F-9CB7-1F00BC261AAF Q37670834-82B64BFF-1413-494D-9F04-A632385E5582 Q37878706-45D01415-82F0-4A74-9785-FC043E818AF8 Q38010258-2CDCDF6C-3AF4-4AB1-9E88-8A75D0E96552 Q38080145-447257F8-1558-4B0C-8FA3-83990A37D992 Q38221036-024B4355-82D6-4FB5-9834-53AE9A76E86E Q39592825-9F141FD8-D8AF-44AE-83C0-E1BACD2F1C85 Q40117212-7F78DCE2-E33C-4CE9-82BA-C4432B10D4BD Q40382144-8C898135-FF4D-491C-B694-084E675B7DAD Q40404536-BCF5B15F-9504-478F-9DE4-D630778DA0D7 Q41072058-F25C80E3-ED13-4395-BB31-8F4B13FE6DFD Q41439919-E22F4CA9-4409-4823-A5A0-1BC90B65B276 Q41542216-E3E4B57A-980F-4E64-9079-B642902944EA Q41564747-6F01FF2F-D5AB-4829-80D1-E9A68E3FF9FA Q41821880-D8D5CE11-40F5-456F-8D8A-778CE8307F45 Q41989294-6C0250B0-1155-4173-85C3-72EAB209E9E5 Q43116397-C10E7F79-55D7-47FF-8CF5-38BA18BDBF70 Q44145967-BEE08356-C95C-408B-A3FD-C3538ECED3AB

P2860

An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.

http://www.wikidata.org/entity/Q39697622

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

An evaluation of risk factors ...... -converting enzyme inhibitors.

@en

An evaluation of risk factors ...... -converting enzyme inhibitors.

@nl

type

label

An evaluation of risk factors ...... -converting enzyme inhibitors.

@en

An evaluation of risk factors ...... -converting enzyme inhibitors.

@nl

prefLabel

An evaluation of risk factors ...... -converting enzyme inhibitors.

@en

An evaluation of risk factors ...... -converting enzyme inhibitors.

@nl

P1433

Q39697622-C87755D4-EE8D-40CD-9F45-D6B2D864D199

P1476

Q39697622-3E092CA0-40F4-4F3C-B9D7-2C67C354F678

P2093

Q39697622-0E1B1E94-DAEB-4F2C-BF83-F30BEAC727AF

Q39697622-134ABDF4-81D4-4428-A69B-B65D5B8A954A

Q39697622-4396E581-7B1F-4712-A8A7-B0F3025BA093

Q39697622-683EE179-FA61-4BD6-B5FF-79B09B1E7E39

Q39697622-72FD4144-CD40-4291-9651-931D7F5B8A37

Q39697622-76521AA3-59D6-4CC8-8285-870E505F26D9

Q39697622-C4174253-6D91-41C2-8314-5F41B4E3B52A

Q39697622-CC4A25B0-7D93-4D0A-832D-D0F69D021856

P2860

Q39697622-0599D64C-C546-4487-88CC-8F9E4C49F052

Q39697622-1F89A28C-D0FD-48F2-B589-31C5C404A863

Q39697622-30905E38-C711-429E-8D3D-55D199AB7CF7

Q39697622-450E765A-5917-4FCF-9263-093763F9F8DF

Q39697622-64CA0A99-4E00-4D8B-A2AC-138BC4C21D72

Q39697622-7D56D45D-960F-45FF-ABC7-EC6A50A3553A

Q39697622-9003C817-785A-4BB7-96F7-588F0D7450C2

Q39697622-9FFD44D6-DAA7-4B27-9853-EA1474C36E9E

Q39697622-A3CE3D2E-E998-4F54-B9D5-70BCF35231B7

Q39697622-ACDAD222-48B1-443A-953B-A0D67CE063A0

P304

Q39697622-617FC0F3-6BF5-4A87-93F6-50F057CB3188

P31

Q39697622-FDCF3B1C-2C39-482A-84AD-CFE74B9919A3

P356

Q39697622-37A51185-4553-4561-AB9C-2D74317880CC

P433

Q39697622-8EE83170-C2D7-45CA-A38B-7E7277808316

P478

Q39697622-490C97F3-F817-4192-B07A-828146DC6462

P577

Q39697622-D6B63AEF-2FBE-4EB3-9556-10944CE44031

P698

Q39697622-27832C6A-EB3A-4DA0-9092-DB428CBC3EDE

P356

J.1365-2753.2003.00484.X

P1433

Journal of Evaluation in Clinical Practice

P1476

An evaluation of risk factors ...... -converting enzyme inhibitors.

@en

P2093

Andrew C Seger

http://www.w3.org/2001/XMLSchema#string

David W Bates

http://www.w3.org/2001/XMLSchema#string

E Francis Cook

http://www.w3.org/2001/XMLSchema#string

Joseph W So

http://www.w3.org/2001/XMLSchema#string

Julie M Fiskio

http://www.w3.org/2001/XMLSchema#string

Takeshi Morimoto

http://www.w3.org/2001/XMLSchema#string

Tejal K Gandhi

http://www.w3.org/2001/XMLSchema#string

Tsuguya Fukui

http://www.w3.org/2001/XMLSchema#string

P2860

Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough

Effect of computerized physician order entry and a team intervention on prevention of serious medication errors

Has the survival of the heart failure population changed? Lessons from trials.

Drug complications in outpatients

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

Adverse drug events in ambulatory care.

Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies.

A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients.

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice.

P304

499-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2753.2003.00484.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15482412

http://www.w3.org/2001/XMLSchema#string